


-55-

CLAIMS

1. A compound of formula



or a pharmaceutically acceptable salt thereof,

5 or a prodrug thereof,

wherein n is an integer of from 1 to 4.

2. A compound according to Claim 1 wherein n is an integer of from 2 to 4.
3. A compound according to Claim 1 wherein the compound is a compound of Formula I.
- 10 4. A compound according to Claim 1 and selected from: add name for  
 $(1\alpha,6\alpha,8\beta)(2\text{-Aminomethyl-octahydro-inden-2-yl})\text{-acetic acid}$ ;  
 $(2\text{-Aminomethyl-octahydro-inden-2-yl})\text{-acetic acid}$ ;  $(2\text{-Aminomethyl-octahydro-pentalen-2-yl})\text{-acetic acid}$ ;  $(2\text{-Aminomethyl-octahydro-pentalen-2-yl})\text{-acetic acid}$ ;  $(3\text{-Aminomethyl-bicyclo[3.2.0]hept-3-yl})\text{-acetic acid}$ ;  
15  $(3\text{-Aminomethyl-bicyclo[3.2.0]hept-3-yl})\text{-acetic acid}$ ; and  
 $(2\text{-Aminomethyl-octahydro-inden-2-yl})\text{-acetic acid}$ .
5. A compound according to Claim 1 and selected from:  
 $(1\alpha,5\beta)(3\text{-Aminomethyl-bicyclo[3.1.0]hex-3-yl})\text{-acetic acid}$ ,  
 $(1\alpha,5\beta)(3\text{-Aminomethyl-bicyclo[3.2.0]hept-3-yl})\text{-acetic acid}$ ,  
20  $(1\alpha,5\beta)(2\text{-Aminomethyl-octahydro-pentalen-2-yl})\text{-acetic acid}$ ,  
 $(1\alpha,6\beta)(2\text{-Aminomethyl-octahydro-inden-2-yl})\text{-acetic acid}$ ,  
 $(1\alpha,7\beta)(2\text{-Aminomethyl-decahydro-azulen-2-yl})\text{-acetic acid}$ ,

-56-

- ( $1\alpha,5\beta$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
( $1\alpha,5\beta$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
( $1\alpha,5\beta$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
( $1\alpha,6\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
5      ( $1\alpha,7\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
      ( $1\alpha,3\alpha,5\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
      ( $1\alpha,3\alpha,5\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
      ( $1\alpha,6\alpha,8\alpha$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
      ( $1\alpha,7\alpha,9\alpha$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
10     ( $1\alpha,3\beta,5\alpha$ )(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,  
      ( $1\alpha,3\beta,5\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,  
      ( $1\alpha,3\beta,5\alpha$ )(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,  
      ( $1\alpha,6\alpha,8\beta$ )(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,  
      ( $1\alpha,7\alpha,9\beta$ )(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,  
15     (( $1R,3R,6R$ )-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
      (( $1R,3S,6R$ )-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
      (( $1S,3S,6S$ )-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
      (( $1S,3R,6S$ )-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,  
      (( $1R,3R,6S$ )-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
20     (( $1R,3S,6S$ )-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
      (( $1S,3S,6R$ )-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
      (( $1S,3R,6R$ )-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,  
      (( $3\alpha R,5R,7\alpha S$ )-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
      (( $3\alpha R,5S,7\alpha S$ )-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
25     (( $3\alpha S,5S,7\alpha R$ )-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
      (( $3\alpha S,5R,7\alpha R$ )-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,  
      (( $2R,4\alpha S,8\alpha R$ )-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
      (( $2S,4\alpha S,8\alpha R$ )-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
      (( $2S,4\alpha R,8\alpha S$ )-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,  
30     (( $2R,4\alpha R,8\alpha S$ )-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,

-57-

- ((2R,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- ((2S,4 $\alpha$ S,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- 5 ((2S,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- ((2R,4 $\alpha$ R,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- 10 ((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
- ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
- ((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
- ((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
- ((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
- ((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
- 15 ((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
- ((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
- ((3 $\alpha$ R,5R,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
- ((3 $\alpha$ R,5S,7 $\alpha$ R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
- ((3 $\alpha$ S,5S,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
- 20 ((3 $\alpha$ S,5R,7 $\alpha$ S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
- ((2R,4 $\alpha$ R,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
- ((2S,4 $\alpha$ S,8 $\alpha$ R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
- ((2S,4 $\alpha$ R,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
- ((2R,4 $\alpha$ S,8 $\alpha$ S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
- 25 ((2R,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- ((2S,4 $\alpha$ R,9 $\alpha$ R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
- ((2S,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid, and

-58-

((2R,4 $\alpha$ S,9 $\alpha$ S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid.

6. A compound according to Claim 1 named (1 $\alpha$ ,3 $\alpha$ ,5 $\alpha$ )(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid.
- 5 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
8. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 10 9. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 10 10. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 15 11. A method for treating depression comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 20 12. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
13. A method for treating panic comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.

25

-59-

14. A method for treating pain comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
15. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.  
5
16. A method for treating premenstrual syndrome comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.